For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously “undruggable” cancer protein target, permanently blocking it. Transcription factors ...

Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose ...

At the ongoing meeting of the American Chemical Society in Denver, F. Hoffmann-La Roche Ltd. has reported the discovery of an orally available and brain-penetrant irreversible asparagine-specific ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it. Transcription factors ...

Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a co-factor that controls transcription by phosphorylating the C-terminal domain of ...